West Virginia University Cancer Institute, Morgantown, WV 26506, USA.
Lane Department of Computer Science and Electrical Engineering, West Virginia University, Morgantown, WV 26506, USA.
Cells. 2022 Dec 26;12(1):101. doi: 10.3390/cells12010101.
There are insufficient accurate biomarkers and effective therapeutic targets in current cancer treatment. Multi-omics regulatory networks in patient bulk tumors and single cells can shed light on molecular disease mechanisms. Integration of multi-omics data with large-scale patient electronic medical records (EMRs) can lead to the discovery of biomarkers and therapeutic targets. In this review, multi-omics data harmonization methods were introduced, and common approaches to molecular network inference were summarized. Our Prediction Logic Boolean Implication Networks (PLBINs) have advantages over other methods in constructing genome-scale multi-omics networks in bulk tumors and single cells in terms of computational efficiency, scalability, and accuracy. Based on the constructed multi-modal regulatory networks, graph theory network centrality metrics can be used in the prioritization of candidates for discovering biomarkers and therapeutic targets. Our approach to integrating multi-omics profiles in a patient cohort with large-scale patient EMRs such as the SEER-Medicare cancer registry combined with extensive external validation can identify potential biomarkers applicable in large patient populations. These methodologies form a conceptually innovative framework to analyze various available information from research laboratories and healthcare systems, accelerating the discovery of biomarkers and therapeutic targets to ultimately improve cancer patient survival outcomes.
目前的癌症治疗中缺乏足够准确的生物标志物和有效的治疗靶点。患者肿瘤的 bulk 组织和单细胞的多组学调控网络可以揭示分子疾病机制。将多组学数据与大规模的患者电子病历(EMR)整合,可以发现生物标志物和治疗靶点。在这篇综述中,我们介绍了多组学数据的协调方法,并总结了分子网络推断的常见方法。我们的预测逻辑布尔蕴涵网络(PLBIN)在构建 bulk 肿瘤和单细胞的基因组规模的多组学网络方面具有优于其他方法的优势,在计算效率、可扩展性和准确性方面均有优势。基于构建的多模态调控网络,可以使用图论网络中心性度量来对候选生物标志物和治疗靶点进行优先级排序。我们将患者队列中的多组学图谱与大规模患者 EMR(如 SEER-医疗保险癌症登记处)进行整合的方法,并结合广泛的外部验证,可识别潜在的适用于大型患者群体的生物标志物。这些方法学形成了一个从研究实验室和医疗保健系统中分析各种可用信息的概念性创新框架,加速了生物标志物和治疗靶点的发现,最终改善了癌症患者的生存结果。